BioTelemetry, Inc. (NASDAQ:BEAT) is reporting third quarter earnings results on Thursday 29th October 2020, after market close.
The consensus estimates from Thomson Reuters are income of $ 0.38 per share.
For the full year, analysts predict revenues of $ 434.35 million, while looking forward to income of $ 1.44 per share.
Previous Quarter Performance
BioTelemetry, Inc. revealed income for the second quarter of $ 0.35 per share, from the revenue of $ 99.11 million. The quarterly earnings dropped 33.96 percent while revenues reduced 10.80 percent compared with the same quarter last year.
According to street consensus, BEAT was expected to report 2Q20 income of $ 0.16 per share from revenue of $ 89.52 million. The bottom line results beat street analysts by $ 0.19 or 118.75 percent, at the same time, top line results outshined analysts by $ 9.59 million or 10.71 percent.
Stock Performance
Shares of BioTelemetry, Inc. traded low $ -1.41 or -3.39 percent on Wednesday, reaching $ 40.17 with volume of 352.90 thousand shares. BioTelemetry, Inc. has traded high as $ 40.85 and has cracked $ 39.47 on the downward trend
According to the previous trading day, closing price of $ 40.17, representing a 52.03 % increase from the 52 week low of $ 27.35 and a 25.55 % decrease over the 52 week high of $ 55.85.
The company has a market capital of $ 1.37 billion and is part of the Healthcare sector and Diagnostics & Research industry.
Conference Call
BioTelemetry, Inc. will be hosting a conference call at 5:00 PM eastern time on 29th October 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.gobio.com
BioTelemetry, Inc., a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core lab services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in Healthcare, Research, and Corporate and Other segments. The Healthcare segment focuses on the remote cardiac monitoring to identify arrhythmias or heart rhythm disorders.
